Screening might help to increase success rate of surgical treatment of one of the world's biggest killers

October 25, 2001

Research data has shown that death rates from colorectal cancer could be cut by 20 per cent, ECCO 11 - the European Cancer Conference in Lisbon heard today. (Thursday 25 October)

Professor John Northover, of the Imperial Cancer Research Fund Colorectal Cancer Unit, St. Marks Hospital, London, said that surgery had been "the mainstay of treatment" for more than a century. Screening could help to improve surgical success rates by identifying people with the disease before they developed symptoms.

Colorectal cancer is the second biggest cancer killer in the UK and other European countries - as well as in the USA and Australia.

Professor Northover said: "Almost nowhere has colorectal cancer screening been introduced as national policy as robust evidence of efficacy has not been available. It has taken almost 20 years to conduct and interpret the necessary randomised trials of faecal occult blood testing" (FOBT). Data from three such trials have shown that death rates could be cut by up to 20 per cent if governments rose to the challenge".

But Professor Göran Ekelund, of the Department of Surgery, University Hospital of Malmo, Sweden, challenged the suggestion that screening would necessarily be beneficial. He said: "The idea of prevention of disease and early detection of cancer is very attractive - especially so when people are told that screening can reduce mortality in cancer by up to 30 per cent. But it is not that simple. There are many sources of bias and error in the studies performed".

Professor Ekelund added that the studies only provided data about the differences in mortality between screened patients and control groups. They had not been informed about how many 'extra survival years' screened people got. This advantage had to be balanced against the discomfort and number of complications occurring in people who did not benefit from screening and any treatment that follows.

"Before any decision is taken, we should have that information which is not yet available. We cannot yet calculate how many people will need to suffer from unnecessary screening. What we can calculate is the NNT (Numbers Needed to Treat), i.e. how many people must be screened bi-annually for ten years to avoid one death in colo-rectal cancer. That figure is around one thousand. The exact cost for a screening programme is not available." Professor Ekelund asked if the resources/costs for screening would need to be taken from other health care resources, leading to additional medical problems.

Professor Northover said that the UK government had set up pilot centres covering two million people to examine the potential of setting up a FOBT based programme. He added: "This will check that a service of the necessary quality can be delivered and establish the true costs. These studies are due to be completed in 2003".

The St. Marks Colorectal Cancer Unit in London is also evaluating the use of a single flexible sigmoidoscopy (FS) to screen people aged around 60 for colorectal cancer. About 170,000 people were randomised, of whom 40,000 received screening.

In his concluding remarks, Professor Ekelund highlighted the importance of addressing and analysing a difficult problem in a balanced way that took account of ethical issues.
Northover 2

Abstracts nos. 1355 (Professor Northover) and 1356 (Professor Ekelund)

Further information: Maria Maneiro
+351 21 892 1818 (till 25 October)
+32 2 775 02 03 (from 26 October)

ECCO-the European CanCer Organisation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to